0001583810-20-000006.txt : 20200115
0001583810-20-000006.hdr.sgml : 20200115
20200115160315
ACCESSION NUMBER: 0001583810-20-000006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200113
FILED AS OF DATE: 20200115
DATE AS OF CHANGE: 20200115
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LOSORDO DOUGLAS W
CENTRAL INDEX KEY: 0001583810
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33650
FILM NUMBER: 20528344
MAIL ADDRESS:
STREET 1: 13 FOX MEADOW RD
CITY: SCARSDALE
STATE: NY
ZIP: 10583
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CALADRIUS BIOSCIENCES, INC.
CENTRAL INDEX KEY: 0000320017
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
IRS NUMBER: 222343568
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 110 ALLEN ROAD
STREET 2: SECOND FLOOR
CITY: BASKING RIDGE
STATE: NJ
ZIP: 07920
BUSINESS PHONE: 908-842-0100
MAIL ADDRESS:
STREET 1: 110 ALLEN ROAD
STREET 2: SECOND FLOOR
CITY: BASKING RIDGE
STATE: NJ
ZIP: 07920
FORMER COMPANY:
FORMER CONFORMED NAME: Caladrius Biosciences, Inc.
DATE OF NAME CHANGE: 20150608
FORMER COMPANY:
FORMER CONFORMED NAME: NeoStem, Inc.
DATE OF NAME CHANGE: 20060906
FORMER COMPANY:
FORMER CONFORMED NAME: PHASE III MEDICAL INC/DE
DATE OF NAME CHANGE: 20030819
4
1
wf-form4_157912217471029.xml
FORM 4
X0306
4
2020-01-13
0
0000320017
CALADRIUS BIOSCIENCES, INC.
CLBS
0001583810
LOSORDO DOUGLAS W
C/O CALADRIUS BIOSCIENCES, INC.
110 ALLEN ROAD, 2ND FLOOR
BASKING RIDGE
NJ
07920
0
1
0
0
See Remarks
Common Stock
2020-01-13
4
A
0
19000
0
A
135197
D
Common Stock
2020-01-13
4
F
0
2601
3.28
D
132596
D
Common Stock
2020-01-14
4
F
0
2190
3.38
D
130406
D
Stock Options (Right to Buy)
3.28
2020-01-13
4
A
0
29000
0
A
2020-01-13
2030-01-13
Common Stock
29000.0
29000
D
Represents 19,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.
Includes 25,575 unvested restricted stock awards.
One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.
Executive Vice President, Global Head of Research and Development and Chief Medical Officer
Douglas W. Losordo, by: /s/Todd C. Girolamo, Esq., Attorney-in-Fact
2020-01-15